Portfolio company
iDEL Therapeutics
Country not known yet
Raised
Not known yet
Latest stage
Not known yet
Rounds recorded
Not known yet
Backed by
2 investors
Sectors
About
This company develops synthetic shuttles for direct cytosolic drug delivery to treat cancer patients.
SourceFunding history · 0
No rounds recorded yet. The agent looks for them over time.
Similar companies
EdiTy Therapeutics
This company develops immune cell delivery platforms to transport therapeutic proteins into diseased cells for patients with cancer and genetic disorders.
NaDeNo
This company develops a nanotechnology drug delivery platform for pharmaceutical partners to encapsulate hydrophobic small molecule drugs for targeted cancer treatments.
Cybrexa
The company develops peptide-drug conjugate therapeutics for oncology patients to deliver anti-cancer agents directly into tumours using a pH-sensitive targeting platform.
THERAtRAME
The company develops small molecule inhibitors targeting tRNA epitranscriptomics to treat resistant and immune-refractory cancers for patients with limited therapeutic options.
Delphia Therapeutics
This biotechnology company develops precision cancer medicines that target tumours by overactivating oncogenic pathways to induce cell death in patients.
TwoStep Therapeutics
The company develops peptide-drug conjugates and targeted therapies for patients with solid tumours.
Callio Therapeutics
The company develops multi-payload antibody-drug conjugates to treat cancer patients.
DualTPharma
This company develops bacteria-based drug delivery systems to transport immunotherapies into solid tumours for cancer patients.